NYSEAMERICAN : NRXS
NeurAxis, Inc. — Key statistics
Healthcare · Biotechnology · United States
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 89.54M |
| Enterprise Value | 81.49M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 12.56M |
| Shares Outstanding | 12.56M |
| Shares Change (YoY) | +46.92% |
| Shares Change (QoQ) | +10.70% |
| Owned by Insiders (%) | 30.55% |
| Owned by Institutions (%) | 22.96% |
| Float | 8.33M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.84 |
| Forward PS | 7.40 |
| PB Ratio | 13.21 |
| P/TBV Ratio | 13.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 15.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.04 |
| Quick Ratio | 2.83 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -73.67 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -139.76% |
| Return on Assets (ROA) | -56.21% |
| Return on Invested Capital (ROIC) | -82.23% |
| Return on Capital Employed (ROCE) | -111.34% |
| Weighted Average Cost of Capital (WACC) | 11.81% |
| Revenue Per Employee | $221,505 |
| Profits Per Employee | -$352,213 |
| Employee Count | 24 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 3.76 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.36 |
| 52-Week Price Change | +136.09% |
| 50-Day Moving Average | 6.83 |
| 200-Day Moving Average | 6.67 |
| Relative Strength Index (RSI) | 47.99 |
| Average Volume (20 Days) | 145,409 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 412,837 |
| Short Previous Month | 377,067 |
| Short % of Shares Out | 3.29% |
| Short % of Float | 4.95% |
| Short Ratio (days to cover) | 2.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.32M |
| Gross Profit | 4.55M |
| Operating Income | -7.68M |
| Pretax Income | -7.68M |
| Net Income | -8.45M |
| EBITDA | -7.61M |
| EBIT | -7.68M |
| Loss Per Share | -$0.78 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 8.32M |
| Total Debt | 279,392 |
| Net Cash | 8.04M |
| Net Cash Per Share | $0.64 |
| Equity (Book Value) | 6.74M |
| Book Value Per Share | 0.54 |
| Working Capital | 6.32M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.62M |
| Capital Expenditures | -12,165 |
| Depreciation & Amortization | 73,228 |
| Net Borrowing | -242,345 |
| Free Cash Flow | -5.63M |
| FCF Per Share | -$0.45 |
Margins
| Measure | Value |
|---|
| Gross Margin | 85.56% |
| Operating Margin | -144.51% |
| Pretax Margin | -144.44% |
| Profit Margin | -144.44% |
| EBITDA Margin | -143.13% |
| EBIT Margin | -144.51% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -46.92% |
| Shareholder Yield | -46.92% |
| Earnings Yield | -10.88% |
| FCF Yield | -6.29% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.00 |
| Price Target Difference | 54.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 109.25% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.77 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |